NCT06110663 2023-11-01
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
Clinical Trials
22 trialsNCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT03991403 2023-04-03
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
Phase 3 Unknown
NCT01656551 2023-03-24
MILES-4
National Cancer Institute, Naples
Phase 3 Unknown
NCT05648071 2022-12-13
SPBPDC
Qianfoshan Hospital
Phase 3 Unknown
NCT05346952 2022-04-26
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT01951469 2022-03-08
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT02743923 2021-12-21
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
The Netherlands Cancer Institute
Phase 3 Unknown
NCT02448797 2021-07-20
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT04768075 2021-02-24
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
Phase 3 Unknown
NCT03912389 2020-09-17
DOMAJOR
Biocad
Phase 3 Unknown
NCT04500704 2020-08-05
ACROSS1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04500717 2020-08-05
ACROSS2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04203485 2020-05-08
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02076477 2020-03-17
OITROLC
Sichuan Cancer Hospital and Research Institute
Phase 3 Unknown
NCT03992885 2019-06-20
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03061058 2017-09-15
Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Unknown
NCT03269162 2017-09-14
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Shanghai University of Traditional Chinese Medicine
Phase 3 Unknown
NCT03193788 2017-06-21
PREMIER
Asan Medical Center
Phase 3 Unknown
NCT02579564 2016-10-21
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Phase 3 Unknown
NCT02001168 2013-12-04
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in Phaseâ… B
Xinjiang Medical University
Phase 3 Unknown
NCT01066195 2010-02-10
Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Samsung Medical Center
Phase 3 Unknown